Scorletti Lab

Publications

Selected papers, newest first. The complete record — more than 50 original articles and reviews — is on Google Scholar below.

Selected publications

  1. Ko YA*, Fisher G*, Scorletti E*, et al. (*co-first) Leveraging academic medical biobanks for recall-by-genotype deep phenotyping studies. Human Molecular Genetics, 2025.
  2. Scorletti E, Saiman Y, Jeon S, Buyco DG, et al. A missense variant in human Perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice. JHEP Reports, 2024;6(1):100902.
  3. Bilson J, Scorletti E. Lipid droplets in steatotic liver disease. Current Opinion in Clinical Nutrition & Metabolic Care, 2024;27(2):91–97.
  4. Scorletti E, Carr RM. A new perspective on NAFLD: focusing on lipid droplets. Journal of Hepatology, 2022;76(4):934–945.
  5. Scorletti E*, Creasy KT*, Vujkovic M, et al. (*co-first) Dietary vitamin E intake is associated with a reduced risk of developing digestive diseases and nonalcoholic fatty liver disease. American Journal of Gastroenterology, 2022;117(6):927–930.
  6. Scorletti E, Afolabi PR, Miles EA, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology, 2020;158(6):1597–1610. ★ Cited in the Cochrane network meta-analysis of nutritional supplementation for fatty liver disease.
  7. Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ, 2018;362:k2734. ★ Incorporated into UK NICE guidance on diagnosing and monitoring fatty liver disease.
  8. Scorletti E, West AL, Bhatia L, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. Journal of Hepatology, 2015;63(6):1476–1483.
  9. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME study. Hepatology, 2014;60(4):1211–1221. ★ Relied upon by the UK National Institute for Health and Care Excellence (NICE) in guideline NG49 for fatty liver disease.
  10. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annual Review of Nutrition, 2013;33:231–248.
Google Scholar ORCID profile